High weight is associated with a greater risk of developing many cancers, and with an increased risk of metastasis. But in some cancers such as renal cell carcinoma, it is also associated with better survival and a better response to immunotherapies in particular. Read More
Biosplice Therapeutics Inc. has entered a collaboration with Novo Nordisk A/S to develop first-in-class drug candidates for the treatment of diabetes. Biosplice is developing highly selective and potent dual-specificity tyrosine-regulated kinase (DYRK) inhibitors to stimulate insulin-secreting β-cell proliferation for the treatment of diabetes. Read More
Sibylla Biotech SpA and the University of Texas MD Anderson Cancer Center have signed a strategic collaboration agreement to discover and develop novel small molecule folding interfering degraders (FIDs) for the treatment of cancer. Read More
Variants in several subunits of the Mediator protein complex are responsible for MEDopathies, which present variable clinical manifestations and modes of inheritance. Researchers from Université de Paris Cité have investigated the role of MED16, a subunit of the evolutionary-conserved Mediator complex, in MEDopathies. Read More
Molecure SA has confirmed the in vitro activity of a molecule binding to a new mRNA target within its mRNA discovery platform. This represents the discovery of another class of molecules binding to a second mRNA biological target, which has been confirmed in in vitro assays. Read More
Even though the treatment options that exist for acute myeloid leukemia (AML) are growing, the clinical outcome of patients is still unfavorable. In AML dysregulation of the tyrosine kinase receptors, including RAS, RAF, MEK and ERK, and of the Aurora kinase family (AURK) exists, are both tied to AML development and progression. Read More
A Caregen Co. Ltd. patent details new peptides acting as autophagy and phagocytosis inducers potentially useful for the treatment of hyperpigmentation. Read More
Researchers from Taipei Medical University have presented data from a study that assessed the role of KH-type splicing regulatory protein (KHSRP, also called KSRP) in clear cell renal cell carcinoma (ccRCC). Read More
Curadev Pharma Ltd. has patented proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting agent via linker acting as HPK1 inhibitors and thus reported to be useful for the treatment of cancer, viral infections and immunological disorders. Read More
Actelion Pharmaceuticals Ltd. has identified pyrazolopyrrolopyridazines acting as platelet-derived growth factor receptor β (PDGFR-β, PDGFRB) inhibitors reported to be useful for the treatment of pulmonary arterial hypertension. Read More
Bivictrix Therapeutics plc’s BVX-001, a first-in-class Bi-Cygni bispecific antibody-drug conjugate (ADC) for the treatment of acute myeloid leukemia (AML), has demonstrated a favorable toxicity profile in an industry standard toxicology model. Read More
McGill University, Université de Montreal, Yeda Research and Development Co. Ltd. and Yissum Research Development Co. have jointly developed anisomycin analogues reported to be useful for the treatment of giardiasis, leishmaniasis, toxoplasmosis and trypanosomiasis. Read More
Sanofi SA and Seagen Inc. have reported antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to topoisomerase I inhibitors through a linker reported to be useful for the treatment of cancer. Read More
Cholangiocarcinoma accounts for about 3% of all gastric tumors. Mutant KRAS is the most prevalent oncogene in cholangiocarcinoma, suggesting a potential role for KRAS inhibitors as a therapeutic approach. Read More
